Name | Company | P/L % | MPV |
|
---|---|---|---|---|
Lord Glendonbrook |
![]() |
Stryker / NYQ:SYK | 465.73% | £396,011.26 |
Lord Glendonbrook |
![]() |
Abbott Laboratories / NYQ:ABT | 399.44% | £349,608.43 |
Lord Sassoon |
![]() |
Abbott Laboratories / NYQ:ABT | 283.56% | £268,489.35 |
Lord Grabiner |
![]() |
Boston Scientific / NYQ:BSX | 138.22% | £166,757.37** |
Baroness Noakes |
![]() |
Smith & Nephew / NYQ:SNN | 45.66% | £101,961.87 |
Lord Mance |
![]() |
Stryker / NYQ:SYK | 42.81% | £99,967.64 |
Lord Glendonbrook |
![]() |
Smith & Nephew / NYQ:SNN | 35.19% | £94,633.75 |
Lord Howard of Rising |
![]() |
Ekf Diagnostics / LSE:EKF.L | 23.95% | £86,764.60 |
Lord Londesborough |
![]() |
Abbott Laboratories / NYQ:ABT | 15.96% | £81,173.50 |
Lord Glendonbrook |
![]() |
Medtronic / NYQ:MDT | 10.66% | £77,463.33** |
Lord Browne of Madingley | Allurion / NYQ:ALUR | -16.01% | £58,791.54 | |
Lord Glendonbrook |
![]() |
Align Technology / NMS:ALGN | -52.87% | £32,988.86 |
Lord Kakkar | Cyte / NMS:CTKB | -55.35% | £31,251.50** |